However, while appreciating that any improvement in neurological status is of importance, we consider it now evident that JAK1/2 inhibition does not afford major benefits in terms of neurological disease in the majority of patients with AGS so far treated. Here, JAK1 is linked to Aicardi-Goutieres syndrome.